Clinical Trials Logo

Clinical Trial Summary

The hypothesis is that Sirolimus, (Rapamycin (R)) which is currently used in organ transplantation and works by blocking the activity of T effector cells but preserving T regulatory cells, as well as by inducing autophagy (protein degradation), will be effective in IBM to slow or stabilize disease progression, helping to maintain patient function and independence. This phase III trial will confirm pilot data showing statistically significant clinical outcomes.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04789070
Study type Interventional
Source University of Kansas Medical Center
Contact Andrew J Heim
Phone 9139459926
Email aheim2@kumc.edu
Status Recruiting
Phase Phase 3
Start date July 1, 2022
Completion date February 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT00769860 - Arimoclomol in Sporadic Inclusion Body Myositis Phase 2/Phase 3
Completed NCT01165008 - Anakinra in Myositis Phase 2/Phase 3
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Active, not recruiting NCT05046821 - Sporadic Inclusion Body Myositis Natural History Study
Recruiting NCT06153108 - Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
Active, not recruiting NCT04659031 - A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) Phase 1
Completed NCT03440034 - Study of Pioglitazone in Sporadic Inclusion Body Myositis Phase 1
Terminated NCT04049097 - Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial Phase 3
Completed NCT00001261 - Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Phase 2
Recruiting NCT05272969 - Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
Completed NCT01734369 - Environmental Risk Factors for Myositis in Military Personnel
Active, not recruiting NCT04975841 - Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells N/A
Recruiting NCT00017914 - Adult and Juvenile Myositis
Completed NCT00917956 - Lithium in Inclusion Body Myositis (IBM) N/A
Completed NCT03633318 - Establishing Muscle Impedance Parameters With Electrical Impedance Myography
Active, not recruiting NCT05721573 - A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis Phase 2/Phase 3
Recruiting NCT05032131 - Cell Therapy for IBM by Muscle Injection of ADSVF Phase 1
Completed NCT03299335 - Molecular Profile of the Evolution of Inclusion Body Myositis N/A
Completed NCT04421677 - Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis Phase 1
Completed NCT02753530 - Study of Arimoclomol in Inclusion Body Myositis (IBM) Phase 2